Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma

Imteyaz Ahmad Khan¹, Safoora Rashid¹, Nidhi Singh¹, Sumaira Rashid¹, Vishwajeet Singh², Deepak Gunjan², Prasenjit Das³, Nihar Ranjan Dash⁴, Ravindra Mohan Pandey², Shyam Singh Chauhan⁵, Surabhi Gupta⁶ & Anoop Saraya¹

Early-stage diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to non-specific symptoms. Circulating miRNAs in body fluids have been emerging as potential non-invasive biomarkers for diagnosis of many cancers. Thus, this study aimed to assess a panel of miRNAs for their ability to differentiate PDAC from chronic pancreatitis (CP), a benign inflammatory condition of the pancreas. Next-generation sequencing was performed to identify miRNAs present in 60 FFPE tissue samples (27 PDAC, 23 CP and 10 normal pancreatic tissues). Four up-regulated miRNAs (miR-215-5p, miR-122-5p, miR-192-5p, and miR-181a-2-3p) and four down-regulated miRNAs (miR-30b-5p, miR-216b-5p, miR-320b, and miR-214-5p) in PDAC compared to CP were selected based on next-generation sequencing results. The levels of these 8 differentially expressed miRNAs were measured by qRT-PCR in 125 serum samples (50 PDAC, 50 CP, and 25 healthy controls (HC)). The results showed significant upregulation of miR-215-5p, miR-122-5p, and miR-192-5p in PDAC serum samples. In contrast, levels of miR-30b-5p and miR-320b were significantly lower in PDAC as compared to CP and HC. ROC analysis showed that these 5 miRNAs can distinguish PDAC from both CP and HC. Hence, this panel can serve as a non-invasive biomarker for the early detection of PDAC.

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths worldwide with a 5-year survival rate of only 9%¹. Most of the times when the PDAC is diagnosed, it is already at an advanced stage where it cannot be resected. Hence, there is an urgent need to find biomarkers for the early detection of PDAC.

MicroRNAs (miRNAs) are a subset of small non-coding RNAs that regulate gene expression at the post-transcriptional level by binding to the 3’ untranslated region (UTR) of target mRNAs². Altered expression of miRNAs has been shown to be involved in the regulation of crucial pathological processes in tumorigenesis, progression and metastasis³-⁵. Aberrant expression of miRNAs has been detected in a wide variety of cancers including breast, lung, colorectal, hepatocellular and even pancreatic cancer⁶-¹⁰. Several groups have shown that expression of miR-21, miR-155, miR-196a and miR-222 increases in pancreatic tumour tissue¹¹-¹⁴. Recent studies have looked at the possibility of using these miRNAs as possible diagnostic and prognostic markers¹⁵,¹⁶. Several reports indicate that miRNA expression profiles could be useful in the diagnosis of specific cancer types¹⁷,¹⁸.

It has been well established that serum contains a large number of stable miRNAs derived from various tissues/organs. Highly expressed miRNAs in specific tissues may leak into circulation as biomarkers for tissue injuries, and recent studies have shown the utility of miRNAs as biomarkers for cancers like pancreatic, colorectal, lung, prostate cancer etc.¹⁹-²³. A few studies have profiled the plasma miRNAs in PDAC and even shown their clinical significance.²⁴

A large, retrospective cohort study in which patients had chronic pancreatitis (CP) of at least five years duration before being diagnosed with PDAC found a 14-fold increased risk in these patients²⁵. Since CP is a known...
and miR-214-5p (p < 0.05), were significantly down-regulated in PDAC compared to CP (Fig. 1e–h). Other four selected miRNAs, namely, miR-30b-5p (p < 0.0001), miR-216b-5p (p < 0.001), miR-320b (p < 0.0001) were significantly up-regulated in PDAC tissue compared to the CP, consistent with the results of the NGS. The ing miR-215-5p (p < 0.0001), miR-122-5p (p < 0.001), miR-192-5p (p < 0.05) and miR-181a-2-3p (p < 0.0001) PDAC cases and 9 CP samples (the same samples used in the NGS). As shown in Fig. 1a–d, four miRNAs includ-
ing miR-215-5p, miR-122-5p, miR-192-5p and miR-181a-2-3p) with the highest fold change between PDAC and CP, and the four most down-
regulated miRNAs (miR-30b-5p, miR-216b-5p, miR-320b, and miR-214-5p) in PDAC versus CP (Table 1).

| S. No | miRNA     | Average NGS read counts (reads per million) | PDAC expression | CP expression | Fold change | Regulation |
|-------|-----------|---------------------------------------------|-----------------|---------------|-------------|------------|
| 1     | miR-122-5p| 29.184                                      | 0.617           | 47.256        | Up          |
| 2     | miR-181a-2-3p| 79.163                                      | 3.920           | 20.1903       | Up          |
| 3     | miR-215-5p| 1051.868                                    | 62.665          | 16.785        | Up          |
| 4     | miR-192-5p| 36,052.908                                  | 4321.683        | 8.342         | Up          |
| 5     | miR-320b  | 1.312                                       | 8.264           | 0.257         | Down        |
| 6     | miR-216b-5p| 6.331                                       | 27.819          | 0.227         | Down        |
| 7     | miR-214-5p| 2.507                                       | 11.281          | 0.222         | Down        |
| 8     | miR-30b-5p| 2.787                                       | 37.094          | 0.075         | Down        |

Table 1. List of 8 most differentially expressed miRNAs between PDAC and CP selected from NGS data.

risk factor for the development of PDAC; it seems a promising idea to screen the CP patients for the malignant transformation associated phenotypic changes. However, till date, no blood-based marker has been shown to be useful in the early detection of PDAC in this high-risk, asymptomatic population. Early diagnosis for PDAC requires markers with high sensitivity and specificity. The standard serum marker, sialylated Lewis blood group antigen CA19-9, is widely used, but its use is limited to monitoring responses to therapy and not as a diagnostic marker.26

To the best of our knowledge, no previous study has used Next Generation Sequencing (NGS) to identify miRNAs expressed in CP. Hence, in the present study, both high-throughput NGS and quantitative reverse transcription PCR (qRT-PCR) assays were used to characterize the miRNA expression profile in FFPE tissue and serum from PDAC and CP patients. The goal was to identify a panel of serum miRNAs that could serve as a diagnostic biomarker for the early detection of PDAC in a high-risk group like CP patients.

Results
Selection of candidate miRNAs from the NGS data. NGS analysis was performed to identify the differentially expressed miRNAs in 27 PDAC, 23 CP, and 10 normal pancreatic tissue specimens from autopsy cases. Results from PDAC and CP groups were compared with the normal pancreas. A miRNA was considered differentially expressed when it had both fold change ≥ 2.0 or ≤ 0.5 and a p-value < 0.05. Based on these criteria, 219 miRNAs were identified to be differentially expressed between patients with PDAC and CP, including 120 up-regulated miRNAs and 99 down-regulated miRNAs. From the list of differentially expressed miRNAs, 8 miRNAs were selected for further validation with qRT-PCR—four up-regulated miRNAs (miR-215-5p, miR-122-5p, miR-192-5p and miR-181a-2-3p) with the highest fold change between PDAC and CP, and the four most down-regulated miRNAs (miR-30b-5p, miR-216b-5p, miR-320b, and miR-214-5p) in PDAC versus CP (Table 1).

Validation of tissue miRNA expression by qRT-PCR. To validate the NGS results, the expression levels of the eight selected miRNAs were measured by qRT-PCR in 26 FFPE tissue samples, which included 17 PDAC cases and 9 CP samples (the same samples used in the NGS). As shown in Fig. 1a–d, four miRNAs including miR-215-5p (p < 0.0001), miR-122-5p (p < 0.001), miR-192-5p (p < 0.05) and miR-181a-2-3p (p < 0.0001) were significantly up-regulated in PDAC tissue compared to the CP, consistent with the results of the NGS. The other four selected miRNAs, namely, miR-30b-5p (p < 0.0001), miR-216b-5p (p < 0.001), miR-320b (p < 0.0001) and miR-214-5p (p < 0.05), were significantly down-regulated in PDAC compared to CP (Fig. 1e–h).

Levels of miRNAs in serum samples by qRT-PCR. The levels of the eight selected miRNAs were measured in 125 serum samples (50 PDAC, 50 CP, and 25 HC) using qRT-PCR. The levels of these miRNAs were then compared among the three groups, including the comparisons between PDAC and CP, and between PDAC and HC. As shown in Fig. 2a–c, three miRNAs including miR-215-5p (p < 0.0001), miR-122-5p (p < 0.01), and miR-192-5p (p < 0.001) were significantly up-regulated in the serum of PDAC patients compared to that of CP patients. Similarly in comparing the PDAC and HC samples, the same three candidate miRNAs (miR-215-5p, miR-122-5p and miR-192-5p) had significantly up-regulated levels (p < 0.0001 for each) in the serum of PDAC patients than in the HC (Fig. 2a–c). However, the serum levels of miR-181a-2-3p, exhibited no significant difference among the three studied groups (p = 0.45, 0.38 and 0.56; Fig. 2d) even though its tissue expression was much higher in PDAC (Fig. 1d).

Regarding the miRNAs that are down-regulated in PDAC, serum from patients with PDAC showed significantly decreased levels of miR-30b-5p (p < 0.001) and miR-320b (p < 0.0001) (Fig. 2e,g), whereas no significant difference was observed in miR-216b-5p (p = 0.766) and miR-214-5p (p = 0.823) levels between the PDAC and CP (Fig. 2f and h).

As shown in Fig. 2a–c, the circulating levels of miR-215-5p, miR-122-5p and miR-192-5p in serum samples gradually increased from HC to CP to PDAC, suggesting their role in tumor progression. It is noteworthy that the difference in levels from HC to CP was not significant; however, between CP and PDAC, the enhancement in their levels became highly significant (Fig. 2a–c). Furthermore, the levels of miR-30b-5p in serum gradually decreased from HC to CP to PDAC, suggesting its role as a tumor suppressor (Fig. 2e).

Table 1. List of 8 most differentially expressed miRNAs between PDAC and CP selected from NGS data.
Further assessment of the expression levels of miR-215-5p, miR-122-5p and miR-192-5p from FFPE tissue samples (Fig. 1a–c) showed an overall upregulation in PDAC tissues which correlated well with the higher levels in PDAC serum samples (Fig. 2a–c). Similarly, the expression levels of miR-30b-5p and miR-320b from FFPE tissue samples (Fig. 1e and g) showed an overall downregulation in FFPE PDAC tissue samples and also in PDAC serum samples (Fig. 2e and g). The serum levels of these miRNAs replicated the expression level patterns seen in FFPE tissues suggesting that these miRNAs could serve as a non-invasive biomarker for the early detection of PDAC.

The tissue and serum levels of the miRNAs were also analyzed according to the stage of PDAC (Tables 2 and 3). The results showed that six of the miRNAs were significantly different between FFPE tissues of CP and early stages of PDAC (Table 2). However, miRNA levels were not different when comparing early stages of PDAC with advanced stages. Similarly, in serum samples of CP and early stages of PDAC, five of the miRNAs showed significantly different levels (Table 3). This suggests that these miRNAs may be relevant for early detection of PDAC.

**Diagnostic value of the differentially expressed miRNAs for PDAC.** It was observed that the relative levels of five miRNAs in the serum of the PDAC patients were significantly different from those of the CP patients and HC (Fig. 2), which was similar to the NGS results. Their diagnostic capability to serve as biomarkers for early detection of PDAC was checked by making receiver operating characteristic (ROC) curves and calculating the area under curve (AUC), sensitivity and specificity for each miRNA. The results demonstrated that all the five significant miRNAs (miR-215-5p, miR-122-5p, miR-192-5p, miR-30b-5p, and miR-320b) could potentially discriminate patients with PDAC from CP and HC (Fig. 3a,b). Among these miRNAs, miR-320b showed the highest diagnostic accuracy for distinguishing PDAC patients from CP with an AUC of 1.00; 95% CI: 0.002–0.054 (Fig. 3a and Table 4). MiR-215-5p (95% CI: 0.664–0.839), miR-192-5p (95% CI: 0.621–0.805), miR-122-5p (95% CI: 0.568–0.760) and miR-30b-5p (95% CI: 0.568–0.760) showed a moderate discrimination with AUC value less than 0.8 (Fig. 3a and Table 4). In addition, serum levels of miR-122-5p, miR-320b and miR-215-5p showed a high discrimination for PDAC from HC with AUC value of 0.988 (95% CI: 0.907–0.999), 0.922 (95% CI: 0.833–0.970) and 0.832 (95% CI: 0.721–0.904) respectively (Fig. 3b and Table 5).

Further ROC curve analyses were performed for combinations of miR-215-5p, miR-122-5p, miR-192-5p, miR-30b-5p, and miR-320b. The AUC of the five-miRNA panel was 0.763 (95% CI: 0.724–0.800; Fig. 3a) for distinguishing PDAC from CP and 0.811 (95% CI: 0.744–0.829; Fig. 3b) for distinguishing PDAC from HC.
Discussion

Early diagnosis of PDAC presents a challenge due to the lack of sensitive and specific biomarkers; hence, there is a need for new early diagnostic tools. Recent studies by Jin et al. and others have demonstrated that miRNAs are stable in serum/plasma and hence, can be readily detected by various assays such as NGS technology, miRNA microarray, and qRT-PCR. More importantly, the unique serum/plasma miRNA expression profiles for pancreatic cancer may serve as fingerprints for their detection. A serum miRNA–based biomarker
Table 3. Comparison of relative expression of miRNAs in serum samples of CP and different stages of PDAC.

| miRNA   | Relative expression in Serum mean ± SD | p-value comparing CP with PDAC stage I + II | PDAC stage I + II with PDAC stage III + IV |
|---------|----------------------------------------|---------------------------------------------|---------------------------------------------|
| miR-215-5p | 1.033 ± 1.638 5.365 ± 5.537 6.196 ± 6.189 | 0.047                                       | 0.651                                       |
| miR-122-5p | 6.732 ± 6.318 11.868 ± 10.561 12.959 ± 13.742 | 0.050                                       | 0.771                                       |
| miR-192-5p | 2.320 ± 2.258 7.914 ± 6.788 6.843 ± 6.570 | 0.044                                       | 0.868                                       |
| miR-181a-2-3p | 0.173 ± 0.264 0.153 ± 0.210 0.165 ± 2.281 | 0.986                                       | 0.895                                       |
| miR-30b-5p | 3.998 ± 3.048 0.211 ± 2.933 0.884 ± 3.940 | 0.036                                       | 0.587                                       |
| miR-216b-5p | 0.115 ± 0.180 0.114 ± 2.297 0.121 ± 1.659 | 0.561                                       | 0.771                                       |
| miR-320b | 25.976 ± 13.702 5.251 ± 5.252 4.347 ± 4.165 | 0.050                                       | 0.499                                       |
| miR-214-5p | 0.113 ± 0.197 0.152 ± 0.220 0.112 ± 0.158 | 0.446                                       | 0.138                                       |

Figure 3. Receiver operating characteristic (ROC) curves of serum miRNAs based on results obtained by qRT-PCR (a) patients with PDAC versus CP, (b) patients with PDAC versus HC.
associated with pancreatic cancer could possibly allow detection of the tumors without invasive procedures such as biopsy and surgery. In this study, the expression levels of tissue miRNAs in PDAC, CP and normal pancreas were determined by NGS. Eight differentially expressed miRNAs were selected and their levels were quantified in serum of PDAC, CP patients and healthy controls by qRT-PCR. The results showed that 5 serum miRNAs; three up-regulated (mir-215-5p, mir-122-5p, and mir-192-5p) and two down-regulated (mir-30b-5p and mir-320b) have strong potential as a biomarker for the early detection of PDAC.

In the current study, a significant increase was observed in the expression of miR-215-5p, miR-122-5p and miR-192-5p in PDAC tissues compared to both CP tissue and normal pancreatic tissue using two different techniques (NGS and qRT-PCR). This suggests their involvement in tumour progression; however, there are conflicting reports in the literature about the role of these miRNAs in various cancers. The expression of miR-215-5p was reported to be up-regulated in gastric cancer and glioma with higher-grade of glioma. But reports in other cancer tissues suggest that it serves as a tumor suppressor. Similarly, a lot of studies have looked at the expression of miR-122-5p in cancer tissues with most of them showing a tumor suppressor role for miR-122-5p. Most studies in pancreatic cancer and hepatocellular carcinoma show that miR-122-5p is underexpressed in tumor tissue. However, studies in renal cell carcinoma and colorectal cancer show overexpression of this miRNA in the tumor tissues. Likewise, controversial results have been reported about the alteration of miR-192-5p in PDAC tissue specimens. While Flammang et al. and Botla et al. reported lower expression of miR-192-5p in PDAC tissue; others have reported increased expression in pancreatic cancer tissue. In fact, ectopic expression of miR-192-5p associates with enhanced cell proliferation and migration, reduced apoptosis and promotes cell cycle progression in pancreatic cancer.

Interestingly, studies measuring the circulatory levels of all these three miRNAs show higher levels in cancer patients compared to controls, which is in concordance with data in the present study. At the blood level, it has been shown that serum miR-215-5p has a relatively high value as a promising biomarker in diagnosing hepatocellular carcinoma and osteosarcoma. In keeping with our findings, different studies identified the up-regulation of miR-122-5p in plasma or whole blood of patients with PDAC. Mazza et al. found that though plasma miR-122-5p levels had low specificity as a diagnostic marker with no significant difference between levels in CP and PDAC patients but it could serve as an independent negative prognostic factor as it significantly associated with tumor stage and metastasis. Studies in other cancer types like hepatocellular carcinoma and colorectal cancer also show increased serum levels of miR-122-5p. Levels of miR-192-5p have also been reported to be higher not only in serum or plasma of pancreatic cancer patients but also in the serum of esophageal squamous cell carcinoma (ESCC) patients.

In contrast to the conflicting literature regarding these upregulated microRNAs, the available reports about the role of miR-30b-5p and miR-320b in cancer are more consistent. The lower expression of both these microRNAs in the present study indicated that they act as tumor suppressors in PDAC. Indeed, miR-30b-5p is found to be down-regulated in numerous human cancers, including PDAC. Qin et al. analyzed the expression of miR-30b-5p in 90 patients of HCC and found that expression of miR-30b-5p was down-regulated in HCC tissue, thus inferring that miR-30b-5p acts as a tumor suppressor. Moreover, another study showed that the expression level of miR-30b-5p in 32 ESCC tissues was significantly lower than that in adjacent normal tissues. Liu et al. also found that miR-30b-5p functions as a tumor suppressor in renal cell carcinoma by targeting cell proliferation, metastasis and epithelial-to-mesenchymal transition. As a member of the miR320 cluster, miRNA-320b has also been identified to play a suppressive role in various tumors, including colorectal cancer and glioma.

### Table 4. Diagnostic performance of the five selected serum miRNAs in discriminating PDAC patients from chronic pancreatitis.

| miRNA   | AUC   | 95% CI       | Cut-off point | Sensitivity % | Specificity % |
|---------|-------|--------------|---------------|---------------|---------------|
| miR-215-5p | 0.763 | 0.664–0.839 | 0.744         | 72            | 72            |
| miR-122-5p | 0.674 | 0.568–0.760 | 5.834         | 98            | 56            |
| miR-192-5p | 0.721 | 0.621–0.805 | 2.055         | 70            | 54            |
| miR-30b-5p | 0.666 | 0.568–0.760 | 1.924         | 70            | 56            |
| miR-320b  | 1.00  | 0.002–0.054 | 8.631         | 100           | 100           |

### Table 5. Diagnostic performance of the five selected serum miRNAs in discriminating PDAC patients from healthy controls.

| miRNA   | AUC   | 95% CI       | Cut-off point | Sensitivity % | Specificity % |
|---------|-------|--------------|---------------|---------------|---------------|
| miR-215-5p | 0.832 | 0.721–0.904 | 0.611         | 72            | 72            |
| miR-122-5p | 0.988 | 0.927–0.999 | 5.834         | 98            | 96            |
| miR-192-5p | 0.720 | 0.604–0.817 | 1.669         | 74            | 60            |
| miR-30b-5p | 0.798 | 0.691–0.883 | 2.741         | 76            | 68            |
| miR-320b  | 0.922 | 0.833–0.970 | 4.168         | 84            | 78            |
and nasopharyngeal carcinoma. Tadano et al. found that miR-320 family, which inhibits cell proliferation, is frequently down-regulated in colorectal adenoma and submucosal invasive carcinoma tissues. A recent study showed that transfection of pancreatic cancer cell lines with miR-320b mimics decreased their proliferation and invasion ability indicating that miR-320b has a tumor-suppressive role.

Since, the present study revealed that the expression pattern of miR-215-5p, mir-122-5p and miR-192-5p is gradually increasing from HC to CP to PDAC (Fig.) while the levels of miR-30b-5p in serum gradually decreased from HC to CP to PDAC, hence, monitoring their serum levels at the stage of CP could be an effective marker for the early detection of PDAC.

Another interesting observation from this study is that pattern of serum miRNA levels does not necessarily correspond to their expression pattern in the tissue. In the present context, expression of miR-181a-2-3p, miR-216b-5p and miR-214-5p were significantly different in PDAC tissue compared to CP tissue by both NGS and qRT-PCR but there was no significant difference in their serum levels between the two groups of patients. This observation is not unique to this study as many other reports show little or no concordance between tissue and circulatory levels of the same microRNA. This indicates that due care should be given to determine the miRNA levels in both tissue and serum as miRNAs showing concordance would serve as better biomarkers.

**Conclusion**

In conclusion, this study identified 5 serum miRNAs (miR-215-5p, miR-122-5p, miR-192-5p, miR-30b-5p and miR-320b) that could differentiate PDAC cases from CP and healthy controls with a high degree of accuracy. Thus, these identified miRNAs could potentially function as early non-invasive diagnostic biomarkers of PDAC. Further studies are needed to validate these findings with larger sample size. Future investigations could also explore the molecular mechanism employed by these miRNAs in the progression of pancreatic ductal adenocarcinoma.

**Materials and methods**

**Ethics statement.** This study was approved by the Institutional Ethics Committee, All India Institute of Medical Sciences, New Delhi, India. Written informed consent was obtained from participants for the use of their tissues and blood samples in this study. All methods were performed in accordance with the relevant guidelines and regulations.

**FFPE tissue and serum sample collection.** Formalin-fixed paraffin-embedded (FFPE) tissue blocks from each group: 27 PDAC patients; 23 CP patients who underwent surgery for pain relief; and normal pancreatic tissue specimens from 10 autopsy cases were included for comparison purposes and used for miRNA profiling by NGS. The serum samples from 50 PDAC patients; 50 CP patients and 25 healthy controls (HC) were processed and stored in -80 °C until further experiments. PDAC was diagnosed on the basis of radiological or histopathological examinations. CP was diagnosed on the basis of clinical diagnostic criteria and radiological examinations. The demographic and clinical variables of the PDAC and CP patients are shown in Tables 6 and 7, respectively. Samples were collected from the Department of Gastroenterology and Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

**RNA isolation from FFPE tissue blocks and serum samples.** One FFPE block was selected from each patient for miRNA analysis. From each of these blocks, three 10-µm sections were cut and taken on fresh slides; the tumour area was marked and micro-dissected after deparaffinization. The tissue from 3 slides (of the same block) was scraped into a 2 ml tube and mixed with the lysis buffer provided in the miRCURY RNA Isolation Kit (Tissue) from Exiqon (Exiqon, USA). The rest of the protocol was according to the instructions pro-

| Characteristics                  | PDAC (%) |
|----------------------------------|----------|
| Age (Mean ± SD) years            | 55.65 ± 11.67 |
| Sex                              |          |
| Male                             | 35 (70%) |
| Female                           | 15 (30%) |
| Abdominal pain                   | 43 (86%) |
| Jaundice                         | 26 (52%) |
| Anorexia                         | 40 (80%) |
| Weight Loss                      | 39 (78%) |
| Diabetes Mellitus                | 13 (26%) |
| Locally advanced disease         | 18 (36%) |
| Lymph node involvement           | 27 (54%) |
| Vascular encasement              | 29 (58%) |
| Metastasis                       | 17 (34%) |

**Table 6.** Clinical characteristics of the PDAC patients (n = 50).
vided in the kit. The integrity of extracted RNA samples was analyzed using Agilent Bioanalyzer 2100 (Agilent Technologies, CA, USA).

Total RNA was extracted and purified from 500 μl of serum using the miRCURY RNA isolation kit – Biofluids (Exiqon, Denmark) following the manufacturer’s instructions. Finally, the RNA was eluted in 50 μl volume.

Library construction and next-generation sequencing. Small RNA libraries were constructed using the Illumina Sample Preparation Kit, following the TruSeq Small RNA Sample Preparation Guide (Illumina, CA, USA).

Library construction and next-generation sequencing. Small RNA libraries were constructed using the Illumina Sample Preparation Kit, following the TruSeq Small RNA Sample Preparation Guide (Illumina, CA, USA). Approximately 500 ng of total RNA was used. The 3′ adaptors were ligated to the specific 3′OH group of miRNAs followed by 5′ adaptor ligation. The ligated products were reverse transcribed (Superscript III, Invitrogen, Whitefield, Bangalore) and amplified by PCR (17 cycles). The amplified libraries were size selected in the range of 140 bp–160 bp followed by overnight gel elution and salt precipitation. Finally, the sequencing library was quantified by qRT-PCR using the Kapa Library Quantification Kit (Kapa Biosystems, Wilmington, MA, USA). The qPCR quantified library was subjected to sequencing on an Illumina sequencer (NextSeq500, Illumina) for 75 bp single-end chemistry.

Bioinformatics analysis of miRNA sequencing data. The adapter sequences and low-quality sequences were removed prior to data analysis. Sequences > = 16 bp and < = 35 bp length were considered for further analysis. All the sequences were aligned to the Homo sapiens genome using bowtie-1.1.1. Aligned reads were extracted and checked for ncRNA (rRNA, tRNA, snRNA and snoRNA) contamination. The unaligned reads to ncRNAs were clustered based on the 100% coverage and similarity to generate the read count. Clustered reads were used for Known miRNA prediction.

Further, homology search of these miRNAs was done against all matured Homo sapiens miRNA sequences retrieved from miRbase-21 database using NCBI-blast-2.2.30 + . Known miRNAs and the read usage statistics reports were generated. DGE (Differential gene expression) analysis was carried out using DESeq tool. A miRNA was considered differentially expressed when the miRNA had both a fold change of ≥ 2 or ≤ 0.5 and a P-value < 0.05. Only differential miRNAs with high abundance reads were selected for further investigation.

Validation of miRNA expression by real-time PCR. The expression levels of the eight candidate miRNAs (miR-215-5p, miR-122-5p, miR-192-5p, miR-181a-2-3p, miR-30b-5p, miR-216b-5p, and miR-214-5p) selected from the NGS data were measured by qRT-PCR. 6 μl of total RNA was converted to cDNA in a 20 μl reaction mixture using the miRCURY LNA Universal cDNA Synthesis Kit (Exiqon, Denmark) following the manufacturer’s instructions. Quantification by real-time PCR was performed on Stratagene Mx3005P thermal cycler (Agilent Technologies, USA), using 4 μl of 1:40 diluted cDNA per tube along with the Exilent SYBR miRNA assay kits (Exiqon, Denmark), and LNA based specific primer assays (Qiagen, Germany). MxPro qRT-PCR software was used for the generation of the data. The miRNA expression was assayed in triplicate. Normalization of the miRNA expression levels was done using U6 as a reference control for tissue miRNAs and UniSp6 as an exogenous control for serum miRNAs. Results were analyzed by checking the relative expression of miRNAs by the 2−ΔΔCT method.

Statistical analysis. Statistical analysis was performed using STATA 14.0 statistical software (Texas, USA) and graphs were generated using GraphPad Prism 8.0. One-way ANOVA test was used to evaluate the differential expression of serum miRNA levels between PDAC, CP patients and healthy individuals. The significance of tissue miRNA expression levels was determined by Mann–Whitney test. The area under the ROC curves (AUC) generated by STATA 14.0 was used to evaluate the performance of the selected miRNAs in discriminating the PDAC from CP and HC. Sensitivity and specificity were calculated at an optimal cutoff point to determine the accuracy of differentially expressed miRNAs. A p-value < 0.05 was considered to be statistically significant.

Received: 24 August 2020; Accepted: 18 January 2021
Published online: 02 February 2021

Table 7. Clinical characteristics of the CP patients (n = 50).

| Characteristics          | CP (%)        |
|--------------------------|---------------|
| Age (Mean ± SD) Years    | 34.02 ± 10.35 |
| Sex                      |               |
| Male                     | 37 (74%)      |
| Female                   | 13 (26%)      |
| Disease Duration (Mean ± SD) Months | 55.96 ± 25.41 |
| Follow-Up Duration (Mean ± SD) Months | 37.04 ± 31.37 |
Di Leva, G., Garofalo, M. & Croce, C. M. microRNAs in cancer. *Ann. Rev. Pathol.* **9**, 287–314 (2014).

Ventura, A. & Jacks, T. miRNAs and Cancer: a little RNA goes a long way. *Cell* **136**, 586–591 (2009).

Tsai, H.-P., Huang, S.-F., Li, C.-F., Chien, H.-T. & Chen, S.-C. Differential microRNA expression in breast cancer with different onset age. *PLoS ONE* **13**, e0191195 (2018).

Wu, Y. et al. Serum Exosomal miR-1290 is a potential biomarker for lung adenocarcinoma. *Onco Targets Ther.* **13**, 7809–7818 (2020).

Shi, Y., Zhuang, Y., Zhang, J., Chen, M. & Wu, S. Identification of tumorigenic and prognostic biomarkers in colorectal cancer based on microRNA expression profiles. *Biomed. Res. Int.* **2020**, 1–8 (2020).

Niu, X. et al. MiR-194 promotes hepatocellular carcinoma through negative regulation of CADM1. *Int. J. Clin. Exp. Pathol.* **13**, 1518–1528 (2020).

Gablo, N. et al. Identification and validation of circulating microRNAs as prognostic biomarkers in pancreatic ductal adenocarcinoma patients undergoing surgical resection. *J. Clin. Med.* **9**, 2440 (2020).

Zhang, Y. et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. *World J Surg* **33**, 698–709 (2009).

Bloomston, M. et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. *JAMA* **297**, 1901–1908 (2007).

Lee, E. et al. Expression profiling identifies microRNA signature in pancreatic cancer. *Int. J. Cancer* **120**, 1046–1054 (2007).

Szafranska, A. E. et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. *Oncogene* **26**, 4442–4452 (2007).

Calatayud, D. et al. Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. *Biomark. Res.* **5**, 8 (2017).

Vila-Navarro, E. et al. MicroRNAs for detection of pancreatic neoplasia: biomarker discovery by next-generation sequencing and validation in 2 independent cohorts. *Ann. Surg.* **265**, 1226–1234 (2017).

Allegra, A. et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (Review). *Int. J. Oncol.* **41**, 1897–1912 (2012).

Lu, J. et al. MicroRNA expression profiles classify human cancers. *Nature* **435**, 834–838 (2005).

Xu, J. et al. Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls: a multicenter study. *Ann. Surg.* **263**, 1173–1179 (2016).

Yu, D.-C., Li, Q.-G., Ding, X.-W. & Ding, Y.-T. Circulating MicroRNAs: potential biomarkers for cancer. *Int. J. Mol. Sci.* **12**, 2055–2063 (2011).

Chen, X. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res.* **18**, 997–1006 (2008).

Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proc. Natl. Acad. Sci. USA* **105**, 10513–10518 (2008).

Vila-Navarro, E. et al. Novel circulating miRNA signatures for early detection of pancreatic neoplasia. *Clin. Transl. Gastroenterol.* **10**, e00029 (2019).

Zhou, X. et al. Plasma microRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. *Gene* **673**, 181–193 (2018).

Raimondi, S., Maisonneuve, P. & Lowenfels, A. B. Epidemiology of pancreatic cancer: an overview. *Ann. Surg.* **259**, 10464 (2019).

Wei, Y., Sun, J. & Li, X. MicroRNA-215 enhances invasion and migration by targeting retinoblastoma tumor suppressor gene 1 in colorectal cancer cells. *Cancer Lett.* **332**, 155–163 (2014).

Yao, J., Zhang, P., Li, J. & Xu, W. MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1. *Oncotarget* **9**, 1097–1104 (2017).

Dai, C., Zhang, Y., Xu, Z. & Jin, M. MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in colorectal adenocarcinoma. *Cancer Cell Int.* **18**, 10 (2018).

Yang, G. et al. HNF-4a inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. *PLoS ONE* **15**, e0230450 (2020).

Papakonstantinou, I. G. et al. Expression of MicroRNAs in patients with pancreatic cancer and its prognostic significance. *Pancreas* **42**, 67–71 (2013).

Saito, Y. et al. MicroRNAs in hepatobiliary and pancreatic cancers. *Front. Genet.* **2**, 66 (2011).

Sun, L. et al. Serum exosomal miR-122 as a potential diagnostic and prognostic biomarker of colorectal cancer with liver metastasis. *J. Cancer* **14**, 630–637 (2020).

Nie, W. et al. MiR-122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box gene 3. *Int. J. Oncol.* **54**, 559–571 (2018).

Flammang, I., Reese, M., Yang, Z., Eble, J. A. & Dhayat, S. A. Tumor-suppressive miR-192-5p has prognostic value in pancreatic ductal adenocarcinoma. *Oncotarget* **6**, 1046–1054 (2017).

Lee, E. et al. Clinical significance of circulating miR-1273g-3p and miR-122-5p in pancreatic cancer. *Front. Oncol.* **10**, 44 (2020).

An, Y. et al. Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma. *World J. Gastroenterol.* **24**, 2596–2604 (2018).
49. Huang, Z. et al. A novel serum microRNA signature to screen esophageal squamous cell carcinoma. Cancer Med. 6, 109–119 (2016).
50. Xiong, Y. et al. MicroRNA-30b targets snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells. J. Cancer 9, 2147–2159 (2018).
51. Qin, X., Chen, J., Wu, L. & Liu, Z. MiR-30b-5p acts as a tumor suppressor, repressing cell proliferation and cell cycle in human hepatocellular carcinoma. Biomed. Pharmacother. 89, 742–750 (2017).
52. Xu, J. et al. miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma. J Thorac Dis 11, 3015–3029 (2019).
53. Liu, W. et al. MiR-30b-5p functions as a tumor suppressor in cell proliferation, metastasis and epithelial-to-mesenchymal transition by targeting G-protein subunit α-13 in renal cell carcinoma. Gene 626, 275–281 (2017).
54. Wang, H. et al. miR-320b suppresses cell proliferation by targeting c-Myc in human colorectal cancer cells. BMC Cancer 15, 748 (2015).
55. Lv, Q.-L. et al. Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma. Oncol. Rep. 38, 959–966 (2017).
56. Li, Y. et al. Overexpression of mitochondria mediator gene TRIAP1 by miR-320b loss is associated with progression in nasopharyngeal carcinoma. PLoS Genet. 12, e1006183 (2016).
57. Tadano, T. et al. MicroRNA-320 family is downregulated in colorectal adenoma and affects tumor proliferation by targeting CDK6. World J. Gastrointest. Oncol. 8, 532–542 (2016).
58. Cao, W. & Zhou, G. lncRNA SNHG12 contributes proliferation, invasion and epithelial–mesenchymal transition of pancreatic cancer cells by absorbing miRNA-320b. Biosci. Rep. 40, 1–11 (2020).
59. Tseng, H.-H. et al. Next-generation sequencing for microRNA profiling: MicroRNA-21-3p promotes oral cancer metastasis. Anticancer Res. 37, 1059–1066 (2017).
60. Bhamari, A. et al. Large scale changes in the transcriptome of Eisenia fetida during regeneration. PLoS ONE 13, e0204234 (2018).
61. Dhar, R. et al. De novo assembly of the Indian blue peacock (Pavo cristatus) genome using oxford nanopore technology and illumina sequencing. Gigascience 8, giz038 (2019).
62. Wu, H. et al. Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. Oncol. Rep. 43, 240–250 (2020).

Acknowledgements
This work was supported by grants from the Department of Biotechnology, New Delhi, India (DBT Sanction Order No. 102/IFD/SAN/3599/2015-2016).

Author contributions
I.A.K. was involved in research design, performed the experiments, analyzed data and wrote the manuscript. S.R. collected specimens and assisted the experiments. N.S. guided some of the experimental designs and edited the manuscript. S.R. collected specimens. V.S. and R.M.P. guided in data analysis. D.G. and S.S.C. helped in research design and guided the experiments. P.D. analyzed and interpreted the histopathological data. N.R.D. provided clinical specimens. S.G. and A.S. conceived the study, guided the experiments and corrected the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to S.G. or A.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021